Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatmentsПодробнее

SABCS: Debu Tripathy Examines Adjuvant Chemotherapy in Breast CancerПодробнее

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical studyПодробнее

Debu Tripathy, MD discusses what will be most impactful at the 2021 Miami Breast Cancer Conference®Подробнее

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancerПодробнее

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatmentПодробнее

Debu Tripathy, MD, regarding the results of the MONARCH-2 studyПодробнее

Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancerПодробнее

Debu Tripathy on Hormone Therapy Compliance in Patients with Breast CancerПодробнее

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20Подробнее

Debu Tripathy, MD, regarding CDK 4/6 inhibitors in the treatment of breast cancerПодробнее

SABCS: Debu Tripathy Discusses Immunotherapy in Breast CancerПодробнее

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast CancerПодробнее

Debu Tripathy, MD discusses the impact of covid on breast cancerПодробнее

Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancerПодробнее

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) studyПодробнее

Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trialПодробнее

Tripathy Discusses a Study of Talazoparib in BRCA-Mutated Advanced Breast CancerПодробнее

Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatmentПодробнее